Literature DB >> 30352049

Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice.

Bin Gu1, Kelly E Carstens1,2, Matthew C Judson1,3, Katherine A Dalton4, Marie Rougié1, Ellen P Clark1, Serena M Dudek2, Benjamin D Philpot1,3,5.   

Abstract

Angelman syndrome (AS) is a neurodevelopmental disorder in which epilepsy is common (~90%) and often refractory to antiepileptics. AS is caused by mutation of the maternal allele encoding the ubiquitin protein ligase E3A (UBE3A), but it is unclear how this genetic insult confers vulnerability to seizure development and progression (i.e., epileptogenesis). Here, we implemented the flurothyl kindling and retest paradigm in AS model mice to assess epileptogenesis and to gain mechanistic insights owed to loss of maternal Ube3a. AS model mice kindled similarly to wild-type mice, but they displayed a markedly increased sensitivity to flurothyl-, kainic acid-, and hyperthermia-induced seizures measured a month later during retest. Pathological characterization revealed enhanced deposition of perineuronal nets in the dentate gyrus of the hippocampus of AS mice in the absence of overt neuronal loss or mossy fiber sprouting. This pro-epileptogenic phenotype resulted from Ube3a deletion in GABAergic but not glutamatergic neurons, and it was rescued by pancellular reinstatement of Ube3a at postnatal day 21 (P21), but not during adulthood. Our results suggest that epileptogenic susceptibility in AS patients is a consequence of the dysfunctional development of GABAergic circuits, which may be amenable to therapies leveraging juvenile reinstatement of UBE3A.

Entities:  

Keywords:  Epilepsy; Neurological disorders; Neuroscience

Mesh:

Substances:

Year:  2018        PMID: 30352049      PMCID: PMC6307939          DOI: 10.1172/JCI120816

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Evolution of epilepsy and EEG findings in Angelman syndrome.

Authors:  L A Laan; W O Renier; W F Arts; I M Buntinx; I J vd Burgt; H Stroink; J Beuten; K H Zwinderman; J G van Dijk; O F Brouwer
Journal:  Epilepsia       Date:  1997-02       Impact factor: 5.864

2.  Seizure-like activity in a juvenile Angelman syndrome mouse model is attenuated by reducing Arc expression.

Authors:  Caleigh Mandel-Brehm; John Salogiannis; Sameer C Dhamne; Alexander Rotenberg; Michael E Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

3.  Perineuronal net degradation in epilepsy.

Authors:  Elyse K Rankin-Gee; Paulette A McRae; Esther Baranov; Stephanie Rogers; Luke Wandrey; Brenda E Porter
Journal:  Epilepsia       Date:  2015-05-29       Impact factor: 5.864

Review 4.  Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy.

Authors:  Y Ben-Ari
Journal:  Neuroscience       Date:  1985-02       Impact factor: 3.590

5.  Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model.

Authors:  Sara Silva-Santos; Geeske M van Woerden; Caroline F Bruinsma; Edwin Mientjes; Mehrnoush Aghadavoud Jolfaei; Ben Distel; Steven A Kushner; Ype Elgersma
Journal:  J Clin Invest       Date:  2015-04-13       Impact factor: 14.808

6.  The E6-Ap ubiquitin-protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region.

Authors:  J S Sutcliffe; Y H Jiang; R J Galijaard; T Matsuura; P Fang; T Kubota; S L Christian; J Bressler; B Cattanach; D H Ledbetter; A L Beaudet
Journal:  Genome Res       Date:  1997-04       Impact factor: 9.043

7.  Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome.

Authors:  T M DeLorey; A Handforth; S G Anagnostaras; G E Homanics; B A Minassian; A Asatourian; M S Fanselow; A Delgado-Escueta; G D Ellison; R W Olsen
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

8.  Aggrecan expression, a component of the inhibitory interneuron perineuronal net, is altered following an early-life seizure.

Authors:  Paulette A McRae; Esther Baranov; Shilpa Sarode; Amy R Brooks-Kayal; Brenda E Porter
Journal:  Neurobiol Dis       Date:  2010-05-19       Impact factor: 5.996

9.  Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.

Authors:  Linyan Meng; Amanda J Ward; Seung Chun; C Frank Bennett; Arthur L Beaudet; Frank Rigo
Journal:  Nature       Date:  2014-12-01       Impact factor: 49.962

10.  Advantages of repeated low dose against single high dose of kainate in C57BL/6J mouse model of status epilepticus: behavioral and electroencephalographic studies.

Authors:  Karen Tse; Sreekanth Puttachary; Edward Beamer; Graeme J Sills; Thimmasettappa Thippeswamy
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

View more
  17 in total

Review 1.  Epilepsy in Angelman syndrome: A scoping review.

Authors:  Debopam Samanta
Journal:  Brain Dev       Date:  2020-09-04       Impact factor: 1.961

2.  Two siblings suffering from Angelman Syndrome with a novel c.1146T>G mutation in UBE3A: A case report.

Authors:  Can Liu; Rui-Hua Liu; Guang-Fei Sun; Lin Yang; Qin-Liang Zheng; Shan-Ying Wei; Qing-Xia Kong; Qiu-Bo Li
Journal:  Biomed Rep       Date:  2022-04-19

Review 3.  Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies.

Authors:  Dylan C Brock; Scott Demarest; Tim A Benke
Journal:  Neurotherapeutics       Date:  2021-09-30       Impact factor: 6.088

4.  Collaborative Cross mice reveal extreme epilepsy phenotypes and genetic loci for seizure susceptibility.

Authors:  Bin Gu; John R Shorter; Lucy H Williams; Timothy A Bell; Pablo Hock; Katherine A Dalton; Yiyun Pan; Darla R Miller; Ginger D Shaw; Benjamin D Philpot; Fernando Pardo-Manuel de Villena
Journal:  Epilepsia       Date:  2020-08-27       Impact factor: 5.864

5.  Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice.

Authors:  Bin Gu; Manhua Zhu; Madison R Glass; Marie Rougié; Viktoriya D Nikolova; Sheryl S Moy; Paul R Carney; Benjamin D Philpot
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

6.  A report on seven fetal cases associated with 15q11-q13 microdeletion and microduplication.

Authors:  Xiuzhu Huang; Jieping Chen; Wenlong Hu; Lu Li; Huiyan He; Hui Guo; Qiuyan Liao; Mei Ye; Donge Tang; Yong Dai
Journal:  Mol Genet Genomic Med       Date:  2021-02-04       Impact factor: 2.183

7.  A cross-species spatiotemporal proteomic analysis identifies UBE3A-dependent signaling pathways and targets.

Authors:  Nikhil J Pandya; Sonja Meier; Stefka Tyanova; Marco Terrigno; Congwei Wang; A Mattijs Punt; E J Mientjes; Audrey Vautheny; Ben Distel; Thomas Kremer; Ype Elgersma; Ravi Jagasia
Journal:  Mol Psychiatry       Date:  2022-03-09       Impact factor: 13.437

8.  Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes.

Authors:  Monica Sonzogni; Johanna Hakonen; Mireia Bernabé Kleijn; Sara Silva-Santos; Matthew C Judson; Benjamin D Philpot; Geeske M van Woerden; Ype Elgersma
Journal:  Mol Autism       Date:  2019-05-22       Impact factor: 7.509

Review 9.  Developmental studies in fragile X syndrome.

Authors:  Khaleel A Razak; Kelli C Dominick; Craig A Erickson
Journal:  J Neurodev Disord       Date:  2020-05-02       Impact factor: 4.025

10.  Simvastatin Restores HDAC1/2 Activity and Improves Behavioral Deficits in Angelman Syndrome Model Mouse.

Authors:  Vipendra Kumar; Tripti Joshi; Naman Vatsa; Brijesh Kumar Singh; Nihar Ranjan Jana
Journal:  Front Mol Neurosci       Date:  2019-11-26       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.